J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23

Max Gelman

Senior Editor

Lei Lei Wu

News Reporter

CHICAGO — When Leyla Shune first heard about a leaked abstract last month describing a dramatic 74% reduction in the risk of disease progression or …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23

Max Gelman

Senior Editor

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Takeda to pay $200M for rights to anemia drug from Keros

Revolution sells $600M in shares on back of RAS inhibitor portfolio updates

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Gilead makes another ADC move, inking up to $415M pact with Tubulis

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

Senior Editor

News Reporter

Sign up to read this article for free.

more like this

J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23